Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 4

Алгоритм выбора терапии когнитивных нарушений в современной клинической практике
В.Н. Шишкова


References

1. Grinin VM, Shestemirova EI. Demographic aging in Russia at the present stage. Bulletin of the Russian Academy of Medical Sciences 2015;70(3):348-54 (In Russian).
2. Shishkova VN. An elderly comorbid patient: prioritizing. Consilium Medicum 2019;21(9):48-53 (In Russian).
3. Shishkova VN, Kotova MB, Kapustina LA, Imamgayazova KE. Issues of pathogenesis of cognitive and psychoemotional disorders in patients with cardiovascular and metabolic diseases. Therapy 2021;50(8):158-63 (In Russian).
4. Shishkova VN, Adasheva TV. Current perspectives in the mechanisms of cognitive impairment development in patients with cardiovascular diseases and opportunities for their improvement. Nervous Diseases 2021;2:41-7 (In Russian).
5. Shishkova VN, Adasheva TV. Cerebrovascular diseases in patients with type 2 diabetes mellitus. SS Korsakov Journal of Neurology and Psychiatry 2021;121(6):114-8 (In Russian).
6. Shishkova VN, Adasheva TV. Novel opportunities for cognitive function improvement in elderly patients in the therapeutic clinical practice. Nervous Diseases 2021;1:59-63 (In Russian).
7. Tkacheva ON, Ostroumova OD, Kotovskaya YuV, Krasnov GS, Kochetkov AI, Pereverzev AP. Deprescribing of glucose-lowering medications in the elderly. Clinical Pharmacology and Therapy 2019;28(3):62-7 (In Russian).
8. Tkacheva ON, Runikhina NK, Kotovskaya YuV, Sharashkina NV, Ostapenko VS. Arterial hypertension management in patients aged older than 80 years and in patients with senile asthenia. Clinical recommendations. Cardiology: News, Opinions, Training 2017;16(1):76-90 (In Russian).
9. Zakharov VV, Yakhno NN. Cognitive disorders in the elderly and senile age. Methodical manual for physicians. Moscow, 2005. 71 p. (In Russian).
10. Levin OS. Diagnosis and treatment of cognitive impairment and dementia in clinical practice. Moscow: MEDpress-inform; 2021. 448 p. (In Russian).
11. Parfenov VA. Dyscirculatory encephalopathy and vascular cognitive disorders. Moscow: IMA-PRESS; 2017. 128 p. (In Russian).
12. Actovegin: instructions for use. Available from: https://www.rlsnet.ru/tn_index_id_111.htm Accessed 2021 Dec 20 (In Russian).
13. Shamalov NV, Stakhovskaya LV, Shetova IM, Anisimov AV. Investigation of the safety and efficacy of combined therapy with citicoline and actovegin in patients with acute ischemic stroke. SS Korsakov Journal of Neurology and Psychiatry 2010;2:13-7 (In Russian).
14. Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (actovegin). Archives of Gerontology and Geriatrics 1989 Sep-Oct;9(2):181-92.
15. Krüger, G, Quadbeck G. [The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism]. Arzneimittelforschung 1972 Feb;22(2):451-6.
16. Lanner G, Argyropoulos G. [Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research]. Wiener Medizinische Wochenschrift 1975;125:681-5.
17. Guekht A, Skoog I, Korczin AD, Zakharov VV, Eeg M, Vigonius U. A randomized double-blind placebo-controlled trial of actovegin in patients with post-stroke cognitive impairment ARTEMIDA study design. Dementia and Geriatric Cognitive Disorders Extra 2013 Dec;3(1):459-67.
18. Søndergård SD, Dela F, Helge JW, Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. European Journal of Sport Science 2016 Oct;16(7):801-7.
19. Cereton: instructions for use. Available from: https://www.rlsnet.ru/tn_index_id_36322.htm Accessed 2021 Dec 20 (In Russian).
20. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annual Review of Psychology 1997;48:649-84.
21. Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM. Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review. Journal of Experimental Pharmacology 2012 Dec;4:163-72.
22. Parnetti L, Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, Villardita C, Senin U. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer’s type. Drugs & Aging 1993 Mar-Apr;3(2):159-64.
23. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics 2003 Jan;25(1):178-93.
24. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mechanisms of Ageing and Development 2001 Nov;122(16):2041-55.
25. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences 2007 Jun;257(1-2):264-9.
26. Tayebati SK, Tomassoni D, Nwankwo IE, Di Stefano A, Sozio P, Cerasa LS, Amenta F. Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain. CNS & Neurological Disorders. Drug Targets 2013 Feb;12(1):94-103.
27. Tamura Y, Takata K, Matsubara K, Kataoka Y. Alpha-glycerylphosphorylcholine increases motivation in healthy volunteers: a single-blind, randomized, placebo-controlled human study. Nutrients 2021 Jun;13(6):2091.
28. Putilina MV. A personalized selection of choline precursors in evidence-based medicine. SS Korsakov Journal of Neurology and Psychiatry 2020;120(6):144-51 (In Russian).
29. Shishkova VN, Malyukova NG, Tokareva RB. The study of Cereton efficacy in complex neurorehabilitation therapy. Lechebnoye Delo 2020;1:55-62 (In Russian).
30. Kamchatnov PR, Abusueva BA, Yevzelman MA, Yesin RG, Kolyak EV, Novikova LB, Prikazchikov SV, Ryabov AG, Umarova HYa, Boyko AN. Efficacy of cereton in acute ischemic stroke: results of the trial SOLNTSE. SS Korsakov Journal of Neurology and Psychiatry 2012;112(3-2):10-4 (In Russian).
31. Buyvolova TV, Glotova ME, Khalak ME, Vashkevich VV. Cereton in the rehabilitation of patients with hemorrhagic stroke. SS Korsakov Journal of Neurology and Psychiatry 2009;109(5-2):58-62 (In Russian).
32. Shakhparova NV, Kadykov AS. The use of choline alfoscerate in patients with post-stroke cognitive impairment. Difficult Patient 2011;9(1):27-30 (In Russian).
33. Shavlovskaya OA. Experience of using Cereton (choline alfoscerate) in clinical practice. Russian Medical Journal 2011;19(9):557-61 (In Russian).
34. Starchina YuA. Cereton in neurological care. Neurology, Neuropsychiatry, Psychosomatics 2011;2:81-5 (In Russian).
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]